organization · Reporting owner

Braslyn Ltd.

Disclosed activity across 6 companies

Tapewire entity: 94911
SEC CIK: 0001642355

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Esperion Therapeutics, Inc.ESPR · Entity 30796	10% owner	October 26, 2018	October 30, 2018
INSEEGO CORP.INSG · Entity 7061	10% owner	December 14, 2020	December 16, 2020
Mirati Therapeutics, Inc.MRTX · Entity 94908	See remarks	January 23, 2024	January 25, 2024
Solid Biosciences Inc.SLDB · Entity 4915	10% owner	March 04, 2019	March 06, 2019
Tango Therapeutics, Inc.TNGX · Entity 1497	10% owner	August 10, 2021	January 04, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Esperion Therapeutics, Inc.

Report date October 26, 2018 · Filed October 30, 2018

Jointly reported with Boxer Asset Management Inc., Tuesday Thirteen Inc., LEWIS JOSEPH, Boxer Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,401,000	Reported balance Holding disclosure · report date 2018-10-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,401,000 F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) Tuesday Thirteen Inc. ("Tuesday Thirteen") and (v) Joseph C. Lewis (collectively, the "Boxer Group"), and indirectly by Joseph C. Lewis. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	1,201,250	Reported balance Holding disclosure · report date 2018-10-26 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,201,250 F2: These securities are owned directly by Boxer Capital and indirectly by Boxer Management and Joseph C. Lewis.
Common StockSEC Table I · non-derivative	Direct	100	Reported balance Holding disclosure · report date 2018-10-26 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 100 F3: These securities are owned directly by Tuesday Thirteen and indirectly by Joseph C. Lewis.
Call OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.00 · Expires 2019-03-15	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-10-26 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F2: These securities are owned directly by Boxer Capital and indirectly by Boxer Management and Joseph C. Lewis.
Call OptionSEC Table II · derivative / convertible security · Conversion / exercise price $60.00 · Expires 2019-03-15	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-10-26 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F2: These securities are owned directly by Boxer Capital and indirectly by Boxer Management and Joseph C. Lewis.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) Tuesday Thirteen Inc. ("Tuesday Thirteen") and (v) Joseph C. Lewis (collectively, the "Boxer Group"), and indirectly by Joseph C. Lewis. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

F2: These securities are owned directly by Boxer Capital and indirectly by Boxer Management and Joseph C. Lewis.

F3: These securities are owned directly by Tuesday Thirteen and indirectly by Joseph C. Lewis.

INSEEGO CORP.

Report date December 14, 2020 · Filed December 16, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,614,830	Last balance in matching sequence After 2020-12-16 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2020-12-14 · Sale · Disposed 1,721,783 · Balance 8,278,217 F2: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $15.01 to $16.005. F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn. Row 2 · 2020-12-14 · Sale · Disposed 178,949 · Balance 8,099,268 F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $16.01 to $16.38. F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn. Row 3 · 2020-12-15 · Sale · Disposed 190,590 · Balance 7,908,678 F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.50 to $15.20. F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn. Row 4 · 2020-12-16 · Sale · Disposed 293,848 · Balance 7,614,830 F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.00 to $14.70. F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

F2: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $15.01 to $16.005.

F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $16.01 to $16.38.

F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.50 to $15.20.

F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.00 to $14.70.

Mirati Therapeutics, Inc.

Report date January 23, 2024 · Filed January 25, 2024

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, MVA Investors, LLC, Davis Aaron I., Dissanayake Shehan Bharatha, Fuglesang Christopher, Lockend Five, LLC

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-01-23 · Disposition to issuer · Disposed 287,866 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-01-23 · Disposition to issuer · Disposed 203,754 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-01-23 · Disposition to issuer · Disposed 3,135,966 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2024-01-23 · Disposition to issuer · Disposed 30,518 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-01-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-01-23 · Disposition to issuer · Disposed 3,201,440 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-01-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-01-23 · Disposition to issuer · Disposed 332,809 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-01-23 · Disposition to issuer · Disposed 3,578,036 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-01-23 · Disposition to issuer · Disposed 1,413,475 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Filing footnotes · ownership attribution and instrument terms

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

Solid Biosciences Inc.

Report date March 04, 2019 · Filed March 06, 2019

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, MVA Investors, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,923,272	Reported balance Holding disclosure · report date 2019-03-04 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 3,923,272 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	11,488	Reported balance Holding disclosure · report date 2019-03-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 11,488 F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	30,210	Reported balance Holding disclosure · report date 2019-03-04 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 30,210 F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Tango Therapeutics, Inc.

Report date August 10, 2021 · Filed January 04, 2022

Jointly reported with LEWIS JOSEPH

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	26,961	Reported balance Holding disclosure · report date 2021-08-10 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 26,961 F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) Joseph C. Lewis, (v) BCTG Holdings, LLC, (vi) MVA Investors, LLC and (vii) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Joseph C. Lewis who is the sole indirect beneficial owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) Joseph C. Lewis, (v) BCTG Holdings, LLC, (vi) MVA Investors, LLC and (vii) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Joseph C. Lewis who is the sole indirect beneficial owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Pandion Therapeutics, Inc.

Report date July 21, 2020 · Filed July 21, 2020

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I., MVA Investors, LLC

Section 16 reporting ended · disclosed 2020-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,107,513	Last balance in matching sequence After 2020-07-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-07-21 · Conversion · Acquired 1,385,291 · Balance 1,385,291 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 3 · 2020-07-21 · Purchase · Acquired 722,222 · Balance 2,107,513 F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	23,622	Reported balance After 2020-07-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-07-21 · Conversion · Acquired 23,622 · Balance 23,622 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-21 · Conversion · Disposed 7,064,136 · Balance 0 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-07-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-07-21 · Conversion · Disposed 120,460 · Balance 0 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 28, 2020 Filed Oct 30, 2020 21:53 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	41,266	$206.50	$8,521,429.00	Disclosure SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 4 Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,965,302 F5 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $206.00 to $206.99. F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	45,896	$205.49	$9,431,169.04	Disclosure SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 3 Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,006,568 F4 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $205.00 to $205.99. F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	38,543	$204.57	$7,884,741.51	Disclosure SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,052,464 F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $204.00 to $204.99. F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	44,959	$203.35	$9,142,322.73	Disclosure SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,091,007 F2 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $203.00 to $203.98. F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC	Pandion Therapeutics, Inc. PAND · Entity 11788	ConversionSeries B Preferred Stock · Derivative	120,460	$0.00	$0.00	Disclosure SEC source: 0000899243-20-019894 · doc4.xml · derivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 23,622 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.nature: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC	Pandion Therapeutics, Inc. PAND · Entity 11788	ConversionSeries B Preferred Stock · Derivative	7,064,136	$0.00	$0.00	Disclosure SEC source: 0000899243-20-019894 · doc4.xml · derivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,385,291 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC	Pandion Therapeutics, Inc. PAND · Entity 11788	PurchaseCommon Stock	722,222	$18.00	$12,999,996.00	Disclosure SEC source: 0000899243-20-019894 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,107,513 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC	Pandion Therapeutics, Inc. PAND · Entity 11788	ConversionCommon Stock	23,622	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-019894 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.nature: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC	Pandion Therapeutics, Inc. PAND · Entity 11788	ConversionCommon Stock	1,385,291	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-019894 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,385,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
June 12, 2020 Filed Jun 16, 2020 19:09 UTC Amendment	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	600,006	$5.60 Strike: $0.00	$3,359,433.59	Disclosure SEC source: 0000899243-20-016700 · doc4a.xml · derivative · entry 4 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,990,420 Underlying: Common Stock · 600,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 9.99% of the issuer's common stock. Read SEC document
June 12, 2020 Filed Jun 16, 2020 19:09 UTC Amendment	Mirati Therapeutics, Inc. MRTX · Entity 94908	Tax withholdingCommon Stock	6	$100.69	$604.14	Disclosure SEC source: 0000899243-20-016700 · doc4a.xml · nonDerivative · entry 3 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135,966 Read SEC document
June 12, 2020 Filed Jun 16, 2020 19:09 UTC Amendment	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	600,006	$0.00	$600.01	Disclosure SEC source: 0000899243-20-016700 · doc4a.xml · nonDerivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2020 Filed Jun 16, 2020 19:09 UTC Amendment	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	600,000	$97.00	$58,200,000.00	Disclosure SEC source: 0000899243-20-016700 · doc4a.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535,966 Read SEC document
June 12, 2020 Filed Jun 16, 2020 17:03 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	600,006	$5.60 Strike: $0.00	$3,359,433.59	Disclosure SEC source: 0000899243-20-016664 · doc4.xml · derivative · entry 4 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,990,420 Underlying: Common Stock · 600,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 9.99% of the issuer's common stock. Read SEC document
June 12, 2020 Filed Jun 16, 2020 17:03 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Tax withholdingCommon Stock	6	$72.80	$436.80	Disclosure SEC source: 0000899243-20-016664 · doc4.xml · nonDerivative · entry 3 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135,966 Read SEC document
June 12, 2020 Filed Jun 16, 2020 17:03 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	600,006	$0.00	$600.01	Disclosure SEC source: 0000899243-20-016664 · doc4.xml · nonDerivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2020 Filed Jun 16, 2020 17:03 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	600,000	$69.00	$41,400,000.00	Disclosure SEC source: 0000899243-20-016664 · doc4.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535,966 Read SEC document
March 10, 2020 Filed Mar 10, 2021 21:30 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	410	$5.60 Strike: $0.00	$2,295.59	Disclosure SEC source: 0000899243-21-011086 · doc4.xml · derivative · entry 13 Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,578,040 Underlying: Common Stock · 410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 09, 2020 Filed Mar 10, 2021 21:30 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	11,971	$5.60 Strike: $0.00	$67,025.63	Disclosure SEC source: 0000899243-21-011086 · doc4.xml · derivative · entry 12 Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,578,450 Underlying: Common Stock · 11,971 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:30 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	275,004	$5.60 Strike: $0.00	$1,539,747.40	Disclosure SEC source: 0000899243-19-006351 · doc4.xml · derivative · entry 4 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,590,426 Underlying: Common Stock · 275,004 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake, and (xi) Christopher Fuglesang (collectively, the "Boxer Group). Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:30 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Tax withholdingCommon Stock	4	$72.80	$291.20	Disclosure SEC source: 0000899243-19-006351 · doc4.xml · nonDerivative · entry 3 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135,966 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake, and (xi) Christopher Fuglesang (collectively, the "Boxer Group). Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:30 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	275,004	$0.00	$275.00	Disclosure SEC source: 0000899243-19-006351 · doc4.xml · nonDerivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake, and (xi) Christopher Fuglesang (collectively, the "Boxer Group). Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:30 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	275,000	$69.00	$18,975,000.00	Disclosure SEC source: 0000899243-19-006351 · doc4.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,860,966 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake, and (xi) Christopher Fuglesang (collectively, the "Boxer Group). Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
November 16, 2017 Filed Nov 20, 2017 16:55 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseWarrant (right to purchase) · Derivative	1,413,475	$13.00 Strike: $0.00	$18,373,761.53	Disclosure SEC source: 0000899243-17-026986 · doc4.xml · derivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,413,475 Underlying: Common Stock · 1,413,475 shares Expires not disclosed F3 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F2 · ownership.direct: These securities are owned directly by Braslyn, which may be deemed to be a member of the Boxer Group. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
November 16, 2017 Filed Nov 20, 2017 16:55 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseWarrant (right to purchase) · Derivative	801,448	$13.00 Strike: $0.00	$10,418,022.55	Disclosure SEC source: 0000899243-17-026986 · doc4.xml · derivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,448 Underlying: Common Stock · 801,448 shares Expires not disclosed F3 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joseph C. Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Boxer Management and Messrs. Lewis, Fuglesang, Reisman, Lieberburg, Dissanayake, and Davis, by virtue of their ownership in Boxer Capital. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interes Read SEC document
November 16, 2017 Filed Nov 20, 2017 16:55 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	255,264	$13.00	$3,318,432.00	Disclosure SEC source: 0000899243-17-026986 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135,966 F2 · ownership.direct: These securities are owned directly by Braslyn, which may be deemed to be a member of the Boxer Group. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
November 16, 2017 Filed Nov 20, 2017 16:55 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	144,736	$13.00	$1,881,568.00	Disclosure SEC source: 0000899243-17-026986 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,372,510 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joseph C. Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Boxer Management and Messrs. Lewis, Fuglesang, Reisman, Lieberburg, Dissanayake, and Davis, by virtue of their ownership in Boxer Capital. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interes Read SEC document
October 03, 2017 Filed Oct 3, 2017 18:21 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	OtherWarrant (right to purchase) · Derivative	78,186	$0.00 Strike: $7.86	$0.00	Disclosure SEC source: 0000899243-17-023345 · doc4.xml · derivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,186 shares Expires 2017-11-21 Read SEC document
October 03, 2017 Filed Oct 3, 2017 18:21 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	OtherWarrant (right to purchase) · Derivative	189,780	$0.00 Strike: $7.86	$0.00	Disclosure SEC source: 0000899243-17-023345 · doc4.xml · derivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189,780 shares Expires 2017-11-21 Read SEC document
October 03, 2017 Filed Oct 3, 2017 18:21 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	OtherCommon Stock	78,186	$7.86	$614,541.96	Disclosure SEC source: 0000899243-17-023345 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,630 F2 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Lieberburg, Reisman, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 03, 2017 Filed Oct 3, 2017 18:21 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	OtherCommon Stock	189,780	$7.86	$1,491,670.80	Disclosure SEC source: 0000899243-17-023345 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227,774 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors"), (iv) Braslyn Ltd., (v) Joe Lewis, (vi) Christopher Fuglesang, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Neil Reisman, (x) Shehan B. Dissanayake, and (xi) Aaron I. Davis (collectively, the "Boxer Group"). Joseph C. Lewis is the sole indirect beneficial owner of and controls Braslyn Ltd. Read SEC document
January 26, 2017 Filed Jan 30, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	28,839	$5.45	$157,172.55	Disclosure SEC source: 0000899243-17-002188 · doc4.xml · nonDerivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,880,702 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 26, 2017 Filed Jan 30, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	19,330	$5.44	$105,155.20	Disclosure SEC source: 0000899243-17-002188 · doc4.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,851,863 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 25, 2017 Filed Jan 25, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	30,600	$5.42	$165,852.00	Disclosure SEC source: 0000899243-17-001947 · doc4.xml · nonDerivative · entry 3 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,832,533 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 24, 2017 Filed Jan 25, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	27,682	$5.32	$147,268.24	Disclosure SEC source: 0000899243-17-001947 · doc4.xml · nonDerivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,801,933 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 23, 2017 Filed Jan 25, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	19,251	$5.27	$101,452.77	Disclosure SEC source: 0000899243-17-001947 · doc4.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,774,251 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 20, 2017 Filed Jan 20, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	23,873	$5.42	$129,391.66	Disclosure SEC source: 0000899243-17-001652 · doc4.xml · nonDerivative · entry 3 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,755,000 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 19, 2017 Filed Jan 20, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	21,085	$5.48	$115,545.80	Disclosure SEC source: 0000899243-17-001652 · doc4.xml · nonDerivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,731,127 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 18, 2017 Filed Jan 20, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	16,200	$5.50	$89,100.00	Disclosure SEC source: 0000899243-17-001652 · doc4.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,710,042 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 17, 2017 Filed Jan 17, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	17,800	$5.50	$97,900.00	Disclosure SEC source: 0000899243-17-001335 · doc4.xml · nonDerivative · entry 3 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,693,842 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 13, 2017 Filed Jan 17, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	52,311	$5.49	$287,187.39	Disclosure SEC source: 0000899243-17-001335 · doc4.xml · nonDerivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676,042 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 12, 2017 Filed Jan 17, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	49,776	$5.50	$273,768.00	Disclosure SEC source: 0000899243-17-001335 · doc4.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,623,731 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 06, 2017 Filed Jan 10, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseWarrant (right to purchase) · Derivative	4,865,430	$5.60 Strike: $0.00	$27,241,542.57	Disclosure SEC source: 0000899243-17-000988 · doc4.xml · derivative · entry 2 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,865,430 Underlying: Common Stock · 4,865,430 shares Expires not disclosed F2 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group). Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document
January 06, 2017 Filed Jan 10, 2017 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock	581,870	$5.60	$3,258,472.00	Disclosure SEC source: 0000899243-17-000988 · doc4.xml · nonDerivative · entry 1 Braslyn Ltd. · CIK 0001642355 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,573,955 F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group). Joe Lewis is the sole indirect beneficial owner of and controls Braslyn. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.